1375470-88-4 Usage
Description
(3S,5S,6R)-3-amino-6-methyl-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-2-one hydrochloride is a piperidine-based organic compound with a hydrochloride salt form. It features a unique stereochemistry and the presence of an amino group, a trifluoroethyl group, a phenyl group, and a methyl group. These structural characteristics make it a promising candidate for research and pharmaceutical applications, particularly in drug discovery and development.
Uses
Used in Pharmaceutical Applications:
(3S,5S,6R)-3-amino-6-methyl-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-2-one hydrochloride is used as a pharmaceutical intermediate for the development of new drugs. Its structural features, including the amino group, make it suitable for binding to target receptors or enzymes, potentially leading to therapeutic effects.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (3S,5S,6R)-3-amino-6-methyl-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-2-one hydrochloride serves as a valuable compound for further exploration. Its specific stereochemistry and functional groups allow researchers to investigate its potential interactions with biological targets and its efficacy in treating various diseases.
Used in Drug Discovery:
(3S,5S,6R)-3-amino-6-methyl-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-2-one hydrochloride is utilized in drug discovery processes to identify novel therapeutic agents. Its unique structure and functional groups make it an interesting candidate for the development of new drugs with potential applications in various medical fields.
Check Digit Verification of cas no
The CAS Registry Mumber 1375470-88-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,7,5,4,7 and 0 respectively; the second part has 2 digits, 8 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1375470-88:
(9*1)+(8*3)+(7*7)+(6*5)+(5*4)+(4*7)+(3*0)+(2*8)+(1*8)=184
184 % 10 = 4
So 1375470-88-4 is a valid CAS Registry Number.
1375470-88-4Relevant articles and documents
Calcitonin gene-related peptide (CGRP) receptor antagonist treatment of migraine
Gras
, p. 869 - 879 (2020/01/21)
Migraine is ranked as the sixth cause of years lost due to disability, with around 1.04 billion migraine sufferers globally. Triptans are considered the standard for acute migraine treatment, but an important number of migraineurs do not respond to them and these drugs are contraindicated in patients with cardiovascular disease. Migraine therapy is currently undergoing tremendous development, i.e., 5-HT1F receptor agonists (ditans), anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies, and small-molecule CGRP receptor antagonists (gepants). Ubrogepant (MK-1620) is a small-molecule, potent and selective CGRP receptor antagonist. In two phase III clinical trials (ACHIEVE I and II), ubrogepant showed, at 2 hours, significant percentages of pain freedom, and absence of the most bothersome symptoms in migraine patients. In a phase III study to assess the long-term (52-week) safety and tolerability, ubrogepant displayed good tolerability, and no signs of hepatic toxicity. In March 2019, the U.S. Food and Drug Administration accepted the new drug application (NDA) for ubrogepant for the acute treatment of migraine.
PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS
-
Page/Page column 21, (2012/05/21)
The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.
